New GIST Treatments by Prof. Merimsky
Case analysis in GIST during a seminar for GIST Patients at Tel Aviv Medical Center (Ichilov).
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Juan Castelan shares his story.
Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.